How many insider trades does FilingIQ track for XGN?

FilingIQ tracks 127 Form 4 insider transactions for XGN (EXAGEN INC.), covering filings from Sep 19, 2019 onwards. 9 of those were filed in the last 90 days.

Are XGN insiders net buyers or net sellers?

Across the full Form 4 history for XGN, 7 transactions (6%) were open-market purchases and 59 (46%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does XGN insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is XGN in?

EXAGEN INC. (XGN) is classified in the Healthcare sector, specifically Diagnostics & Research, with a current market capitalisation of $86.12M.

XGN insider trading

NasdaqGM Healthcare

EXAGEN INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

127

Last 90 days

Buys / sells

6% / 46%

Market cap

$86.12M

About EXAGEN INC.

Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Company website: www.exagen.com

XGN insider activity at a glance

FilingIQ has scored 127 insider transactions for XGN since Sep 19, 2019. The most recent filing in our index is dated Mar 12, 2026.

Across the full history, 7 open-market purchases and 59 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on XGN insider trades is 54.1/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live XGN trades on FilingIQ Raw filings on SEC EDGAR

Latest XGN Form 4 filings

ABALLI JOHN President and CEO

S Mar 3, 2026

ABALLI JOHN President and CEO

P May 16, 2024

ABALLI JOHN President and CEO

S Oct 17, 2023

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Top insiders trading XGN

ABALLI JOHN

6 trades · score 69.3

Frequently asked

How many insider trades does FilingIQ track for XGN?: FilingIQ tracks 127 Form 4 insider transactions for XGN (EXAGEN INC.), covering filings from Sep 19, 2019 onwards. 9 of those were filed in the last 90 days.
Are XGN insiders net buyers or net sellers?: Across the full Form 4 history for XGN, 7 transactions (6%) were open-market purchases and 59 (46%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does XGN insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is XGN in?: EXAGEN INC. (XGN) is classified in the Healthcare sector, specifically Diagnostics & Research, with a current market capitalisation of $86.12M.

Methodology & sources

Every XGN insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.